SGLT2i Use for HF Rises in the US, But Not in All Hospitals

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

The use of SGLT2 inhibitors for the treatment of heart failure rose in the United States, particularly among younger patients, those with mildly reduced ejection fraction, and Medicaid recipients.
Medscape Medical News